p53 over‐expression is an early event in the development of human squamous‐cell carcinoma of the larynx: Genetic and prognostic implications
Authors:
- Riccardo DolcettiRiccardo Dolcetti
- Claudio DoglioniCDClaudio Doglioni
- Roberta MaestroRMRoberta Maestro
- Daniela GasparottoDGDaniela Gasparotto
- Luigi BarzanLBLuigi Barzan
- Antonio PastoreAPAntonio Pastore
- 9 September 1992
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 52 (2) , 178-182
Abstract
The tumor-suppressor protein p53 is over-expressed in a large fraction of squamous-cell carcinomas of the larynx (LSCCs). p53 overexpression is dependent upon the synthesis of mutated versions of the protein and has been associated with the malignant progression of certain tumor types. In order to examine the prognostic value of p53 immunodetection in LSCCs, we performed a retrospective analysis on a selected series of tumors, using the PAb 1801 and CMI antibodies. No significant difference in the frequency of p53 over-expression was observed between tumors from patients with early relapse (67%) and those who had been disease-free for more than 5 years (84%). The lack of correlation of p53 immunoreactivity with clinical stage and differentiation grade of LSCCs, together with the coordinated expression of pS3 in primary tumors and the corresponding lymph-node metastases, indicate that p53 over-expression is probably unrelated to the biological aggres-siveness of these tumors. In addition, the detection of p53 immunostaining in pre-invasive areas as well as in preneoplastic lesions suggests that p53 abnormalities probably constitute a very early event in LSCC development.Keywords
This publication has 16 references indexed in Scilit:
- p53 in chronic myelogenous leukemia in acute phase.Proceedings of the National Academy of Sciences, 1991
- p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.Proceedings of the National Academy of Sciences, 1991
- Different Tumor-Derived p53 Mutants Exhibit Distinct Biological ActivitiesScience, 1990
- Increased expression of mutant forms of p53 oncogene in primary lung cancerThe Lancet, 1990
- Wild-type p53 can inhibit oncogene-mediated focus formation.Proceedings of the National Academy of Sciences, 1989
- Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia.Proceedings of the National Academy of Sciences, 1989
- The p53 proto-oncogene can act as a suppressor of transformationCell, 1989
- Chromosome 17 Deletions and p53 Gene Mutations in Colorectal CarcinomasScience, 1989
- Isolation of human‐p53‐specific monoclonal antibodies and their use in the studies of human p53 expressionEuropean Journal of Biochemistry, 1986
- INTRAEPITHELIAL CARCINOMA (CANCER IN SITU) OF THE LARYNXA.M.A. Archives of Otolaryngology, 1952